Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study

Satellos Bioscience (NASDAQ: MSLE; TSX: MSCL) will host an investor call on November 6, 2026, to discuss its BASECAMP clinical and regulatory strategy.

Rhea-AI Summary

Satellos Bioscience (NASDAQ: MSLE; TSX: MSCL) will host an investor call on November 6, 2026, to discuss its BASECAMP clinical and regulatory strategy. The conference call and audio webcast will begin at 8:00 a.m. ET. BASECAMP is the company’s Phase 2 pediatric study in boys ages 7, 8 or 9 with Duchenne muscular dystrophy. Chief Executive Officer Frank Gleeson and Chief Medical Officer Wildon Farwell will provide remarks. A live webcast and accompanying slides will be available on the company’s investor website, with a replay available after the presentation.

Argus 15 min delay 7 alerts

+2.05% vs previous close $6.48 last price 3.8x rel. volume Open Argus

Details

Market Reaction – MSLE

$6.09 – $6.89 Day Range

$137.48M Mkt Cap at Last Price

On Nov 5, the day this news came out, the latest delayed price for MSLE is 2.05% above the previous close. Our momentum scanner has recorded 7 alerts for this stock so far that day. The latest delayed price is $6.48. Relative volume is very high at 3.8x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Terms

aak1 inhibitor, investigational new drug (ind) application, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy

4 terms

aak1 inhibitor technical

"an orally administered small molecule AAK1 inhibitor"

An AAK1 inhibitor is a drug or compound that blocks the activity of adaptor-associated kinase 1 (AAK1), a cellular enzyme that regulates clathrin-mediated endocytosis and other intracellular trafficking processes. By reducing AAK1’s kinase activity, these inhibitors can alter how cells internalize receptors and particles (including some viruses) and are developed as investigational therapies; their effects depend on potency and selectivity because AAK1 shares similarity with other kinases and off-target activity can cause unintended cellular effects.

investigational new drug (ind) application regulatory

"An Investigational New Drug (IND) application to initiate clinical research"

An investigational new drug (IND) application is a formal request submitted to a drug regulator asking permission to begin testing a new medicine in people. It compiles lab results, manufacturing details and proposed human trial plans so regulators can judge safety before human studies start; for investors, an accepted IND is a key milestone that opens the clinical development pathway and can materially change a company’s risk profile and potential value, like getting a license to road-test a prototype.

duchenne muscular dystrophy medical

"with Duchenne muscular dystrophy (DMD)"

A rare, inherited condition that progressively weakens muscles, Duchenne muscular dystrophy causes the body’s muscle fibers to break down over time, often leading to severe disability. For investors, it matters because the small, well-defined patient population, high unmet medical need and complex regulatory and pricing dynamics mean successes or failures in clinical trials, approvals, or therapies can have outsized effects on a company’s valuation and future revenue prospects.

facioscapulohumeral muscular dystrophy medical

"for the treatment of facioscapulohumeral muscular dystrophy (FSHD)"

A genetic progressive muscle disorder that slowly weakens the face, shoulder blades and upper arms, often making everyday actions like smiling, lifting objects or raising the arms harder over time. Investors care because it represents a clear unmet medical need: treatments or tests that slow progression, restore function, or improve diagnosis can command significant demand and regulatory attention, similar to developing a new fix for a widespread, uncontrolled mechanical fault in a critical system.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to host a conference call and audio webcast tomorrow at 8:00 a.m. ET

TORONTO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage biotechnology company developing potentially life-improving medicines to treat degenerative muscle disorders, today announced that it will host a conference call and audio webcast at 8:00 a.m. ET on Friday, Nov. 6, 2026, to provide an update on the clinical and regulatory strategy for BASECAMP, the Company’s Phase 2 pediatric study in boys ages 7, 8 or 9 with Duchenne muscular dystrophy (DMD). The call will feature remarks from Satellos Co-founder and Chief Executive Officer Frank Gleeson and Chief Medical Officer Wildon Farwell, M.D.

A live webcast of the conference call and accompanying slides will be available on the Events and Presentations page of the Investors section of the Company’s website. A replay will be available following the presentation.

Conference Call Details
Domestic: 1-877-269-7751
International: 1-201-389-0908
Webcast

ABOUT SATELLOS BIOSCIENCE INC.
Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed forazapadin, an orally administered small molecule AAK1 inhibitor designed to address deficits in muscle repair and regeneration. Forazapadin is being evaluated as a potential disease-modifying treatment for DMD in two Phase 2 clinical trials, BASECAMP in pediatric participants with DMD and TRAILHEAD in adults living with DMD. An Investigational New Drug (IND) application to initiate clinical research into forazapadin for the treatment of facioscapulohumeral muscular dystrophy (FSHD) has also been cleared. The company has identified additional muscle diseases and injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and plans to pursue these opportunities in future clinical development. For more information, visit www.satellos.com and connect with Satellos on X, LinkedIn, Facebook and Instagram.

NOTICE ON FORWARD-LOOKING STATEMENTS
This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the therapeutic potential of forazapadin, including its potential to represent a disease-modifying approach to the therapeutic treatment of people living with DMD and FSHD; the potential of Satellos’ approach in other degenerative muscle diseases and its plans to pursue additional muscle diseases and injury conditions in future clinical development. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are “forward-looking information or statements.” Often, but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “believe”, “plan”, “expect”, “intend”, “estimate”, “anticipate”, “potential”, “prospective”, “assert” or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of Satellos. These statements are based on assumptions and subject to risks and uncertainties. In making forward looking statements, Satellos has relied on various assumptions, including but not limited to: its ability to obtain future funding on favorable terms, if at all; obtaining positive results in its clinical trials, its ability to obtain necessary regulatory approvals; its ability to arrange for the manufacturing of its product candidates and technologies; and general business, market and economic conditions. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting Satellos, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of Satellos generally, including inflation and the costs of operating a biopharma business, and those risks and uncertainties described in more detail in the “Risk Factors” section of Satellos' Annual Information Form dated March 27, 2026, and amended and restated short form base shelf prospectus dated August 11, 2026 (each of which is located on Satellos' SEDAR+ profile) and incorporated by reference in Satellos’ Form F-10 filed with the Securities and Exchange Commission on August 11, 2026, and in Satellos' public filings on EDGAR (sec.gov) and SEDAR+ (sedarplus.ca). Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise.

CONTACTS
Investors: Caitlin Lowie, Vice President, Investor Relations & Communications, ir@satellos.com
Media: Emily Williams, Senior Director, Communications, media@satellos.com